ABSTRACT Introduction: Systemic Lupus Erythematosus (SLE) is a chronic B cell-mediated
autoimmune disease which can potentially involve several organs and systems. The …

Systemic lupus erythematosus (SLE) is a complicated autoimmune disease characterized by
aberrant B cell activation. Belimumab is a human monoclonal antibody, which can reduce …

Introduction This analysis aims to describe real-world clinical outcomes in US African
American and Hispanic patients with systemic lupus erythematosus (SLE) receiving …

Objective To investigate predictors of response, remission, low disease activity, damage,
and drug discontinuation in patients with systemic lupus erythematosus (SLE) who were …

Belimumab is an effective and safe treatment option for systemic lupus erythematosus (SLE).
However, data on treatment cessation are lacking. Thus, we investigated belimumab-free …

Background Large-scale clinical trials have demonstrated clinical efficacy of belimumab in
SLE patients. Objectives This study examined the clinical outcomes associated with …

Objectives To evaluate the risk of psychiatric disorders and all-cause mortality associated
with belimumab therapy in patients with SLE. Methods A literature search of four electronic …

Objective To generate comparative efficacy evidence of belimumab versus anifrolumab in
SLE that can inform treatment practices. Methods The SLE Responder Index (SRI)-4 …

OBSErve Germany was the first observational study of belimumab as add-on treatment for
systemic lupus erythematosus (SLE) in routine clinical care in Germany, retrospectively …

Systemic lupus erythematosus (SLE), a complex autoimmune disease with multisystem
involvement, is characterised by recurring flares and remissions throughout the course of …